Marker sequences for diagnosing prostate cancer, and use thereof

A method for risk stratification, or for therapy control of a patient with prostate carcinoma, while excluding inflammatory prostate diseases or diabetes or polymorbidity, comprising determining at least one marker sequence selected from the group SEQ 1-246 and/or SEQ 247-452 or respectively a protein coded thereby or respectively a from partial sequence or fragment thereof on or from a patient to be examined.

Assay, protein biochip comprising an arrangement containing at least one marker sequence of a cDNA respectively selected from the group SEQ 1-246 and/or SEQ 247-452 or respectively a protein coded thereby or respectively from a partial sequence or fragment thereof, characterized in that the marker sequence(s) is/are applied to a solid support and wherein the marker sequence(s) was/were identified with a method including the steps

• a) Identification of marker sequence candidates using differential screening with protein biochips from respectively a cDNA expression bank of a patient who has prostate cancer and a subject who does not have prostate cancer,
• b) Validation of the marker sequence candidates by means of samples from patients who have inflammatory prostate disease(s) and/or samples from patients who have diabetes.